Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Martek plans offsets for formula contracts

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences CEO Steve Dubin says the nutritional oils firm will offset price reductions in extended infant formula supply contracts with Mead Johnson and Danone through formula market growth, new production technologies and expansion of its Amerifit Brands business. Dubin said during an earnings call Sept. 1 that Amerifit will launch five to seven supplement stock-keeping units in 2011 (1"The Tan Sheet" Aug. 16, 2010). Martek reported cost reductions in life'sDHA and life'sARA production, and efficiencies from Amerifit - acquired in January - helped swell its third-quarter gross margin to nearly 50 percent from 44 percent in the year-ago period. Dubin said he expects further margin, revenue and earnings growth in 2011. The Columbia, Md.-based firm recorded net sales of $114 million in the May-July timeframe, a 51.9 percent increase

You may also be interested in...

Martek Plans 2011 Supplement Launches Through Amerifit Subsidiary

Martek Biosciences' dietary supplement pipeline comes into focus as the developer of algae-based omega-3 oils lines up a slate of products to launch in 2011 through its Amerifit Brands business

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts